The distinctive nature of HER2-positive gastric cancers

被引：13
|
作者：
Marano, L. [1 ]
Roviello, F. [1 ]
机构：
[1] Univ Siena, Dept Med Surg & Neurosci, Unit Gen & Minimally Invas Surg, I-53100 Siena, Italy
来源：
EJSO | 2015年 / 41卷 / 03期
关键词：
HER2; EXPRESSION; RECEPTOR; PROTEIN;
D O I：
10.1016/j.ejso.2014.12.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：271 / 273
页数：3
相关论文
共 50 条
  • [1] Effect of Cellular Senescence on the Growth of HER2-Positive Breast Cancers
    Zacarias-Fluck, Mariano F.
    Morancho, Beatriz
    Vicario, Rocio
    Luque Garcia, Antonio
    Escorihuela, Marta
    Villanueva, Josep
    Rubio, Isabel T.
    Arribas, Joaquin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (05):
  • [2] Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
    Zhou, Chenfei
    Feng, Xiaojing
    Yuan, Fei
    Ji, Jun
    Shi, Min
    Yu, Yingyan
    Zhu, Zhenggang
    Zhang, Jun
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3945 - 3954
  • [3] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
    Li, Zhifei
    Zhao, Huan
    Hu, Huihui
    Shang, Haili
    Ren, Yongjing
    Qiu, Wenhui
    Su, Hao
    Lyu, Huifang
    Chen, Xiaobing
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (03)
  • [4] Clinicopathologic Features and Prognosis of HER2-Positive Gastric Cancer
    Kung, Ching-Yun
    Huang, Kuo-Hung
    Lin, Shih-Chieh
    Hung, Yi-Ping
    Chen, Ming-Huang
    Chao, Yee
    Lo, Su-Shun
    Wu, Chew-Wun
    Li, Anna Fen-Yau
    Fang, Wen-Liang
    Lan, Yuan-Tzu
    INTERNATIONAL SURGERY, 2024, 108 (02) : 68 - 77
  • [5] Biologicals to direct nanotherapeutics towards HER2-positive breast cancers
    Kumar, Gautam
    Nandakumar, Krishnadas
    Mutalik, Srinivas
    Rao, Chamallamudi Mallikarjuna
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2020, 27 (27)
  • [6] Comparison of Clinicopathologic Parameters and Survivals Between Epstein-Barr Virus-positive and Her2-positive Gastric Cancers
    Irkkan, Cigdem
    Balci, Serdar
    Tezel, Gaye Guler
    Akinci, Bulent
    Yalcin, Bulent
    Guler, Gulnur
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2017, 25 (09) : 609 - 614
  • [7] Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
    Yoshioka, Takahiro
    Shien, Kazuhiko
    Namba, Kei
    Torigoe, Hidejiro
    Sato, Hiroki
    Tomida, Shuta
    Yamamoto, Hiromasa
    Asano, Hiroaki
    Soh, Junichi
    Tsukuda, Kazunori
    Nagasaka, Takeshi
    Fujiwara, Toshiyoshi
    Toyooka, Shinichi
    CANCER SCIENCE, 2018, 109 (04) : 1166 - 1176
  • [8] The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
    Castagnoli, Lorenzo
    Ladomery, Michael
    Tagliabue, Elda
    Pupa, Serenella M.
    CANCERS, 2019, 11 (07)
  • [9] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
    Kotani, Daisuke
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [10] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
12345